STENTYS 世界第一的医疗技术商业化公司STENTYS为其第一个治疗急性心肌梗塞的Self-apposing扩展技术的欧洲商业发布了一个增强传输系统。

STENTYS announces European commercial release of new Self-Apposing stent technology

STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the European commercial release of an enhanced stent-delivery system for its Self-Apposing® stent.    

Stents are implanted in the coronary arteries via a keyhole in the groin or in the wrist under angiography (X-ray imaging). Cardiologists use a delivery catheter to navigate through the arteries, reach the occluded vessel and deploy the stent. The new catheter to implant the STENTYS Self-Apposing stent adds a hydrophilic (slippery) coating and an ergonomic handle that considerably facilitates stent implantation in tortuous vessels.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, commented: "Feedback from cardiologists suggests the new delivery catheter is very user-friendly and we are confident this product enhancement will allow a greater range of patients to benefit from our STENTYS Self-Apposing stent technology."

In its latest guidelines on AMI treatment, the European Society of Cardiology (ESC) calls attention to the importance of selecting the appropriate stent size, as the vessel in this setting is contracted and contains thrombus (clot), and to the complications that may result from inappropriate stent sizing. The STENTYS Self-Apposing® Stent solves that "stent-sizing dilemma": it fits into the contour of a blood vessel, and its shape and diameter adapt as the vessel dilates and the initial clot dissolves during the post-AMI phase.